RE: Breaking 40p28 Dec 2021 15:54
Dr Suzy Dilly, CEO of ValiRx commented "This amendment updates the VAL201 license terms in a manner that aligns the license with of the proposed terms of the sub-license between ValiRx and TheoremRx. This is an important step in the process of confirming the licensing documentation for the sub-license, and will enable the proposed transaction to progress without delay. The approval by CRT of the sub-license is also a step-wise progression towards full execution of the agreements."
Suzy stated no delay expected and even if we had one she would have to RNS with a new timeline this week and it would be a very short one. Regardless we have significant upside here to factor in the deal so a great entry point at current SP. It's an investment so hold and with further deals in 2022 it is a multibagger from here imo with very limited risk/downside. Institutional investors to join the party soon as well so all looks fantastic.